Amgen Inc (AMGN)

AMGN (NASDAQ:Drugs) EQUITY
$143.45
pos +0.00
+0.00%
Today's Range: 141.00 - 144.58 | AMGN Avg Daily Volume: 3,889,600
Last Update: 12/09/16 - 4:00 PM EST
Volume: 0
YTD Performance: -11.63%
Open: $0.00
Previous Close: $140.59
52 Week Range: $133.64 - $176.85
Oustanding Shares: 743,922,473
Market Cap: 104,588,060,479
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 4
Moderate Buy 1 1 1 1
Hold 11 11 11 10
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.41 2.41 2.41 2.37
Latest Dividend: 1.00
Latest Dividend Yield: 2.85%
Dividend Ex-Date: 11/14/16
Price Earnings Ratio: 12.43
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
12.43 14.90 31.10
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-13.87% -9.15% 25.86%
GROWTH 12 Mo 3 Yr CAGR
Revenue 8.00 0.20 0.08
Net Income 34.50 0.60 0.17
EPS 35.20 0.60 0.18
Earnings for AMGN:
EBITDA 10.63B
Revenue 21.66B
Average Earnings Estimates
Qtr (12/16) Qtr (03/17) FY (12/16) FY (12/17)
Average Estimate $2.78 $2.89 $11.53 $12.30
Number of Analysts 11 6 13 13
High Estimate $2.89 $3.03 $11.65 $14.03
Low Estimate $2.63 $2.77 $11.39 $11.47
Prior Year $2.61 $2.90 $10.38 $11.53
Growth Rate (Year over Year) 6.34% -0.34% 11.11% 6.61%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA
By

Bret Jensen

 | Dec 8, 2016 | 11:00 AM EST
If the market is going to overreact to every new missive from Trump, I plan to take advantage.
RMPIA
By

David Peltier

 | Nov 10, 2016 | 1:30 PM EST
Check out these 15 stocks that boast solid dividend yields and are growing earnings.
RMPIA
By

Bob Byrne

 | Nov 4, 2016 | 7:00 AM EDT
But we could see more volatility in the market.
RMPIA
By

Bob Byrne

 | Oct 31, 2016 | 7:00 AM EDT
I continue to believe downside risks far outweigh the risks of a near-term rally.
RMPIA
By

James "Rev Shark" DePorre

 | Oct 30, 2016 | 10:00 AM EDT
tk
RMPIA
By

James "Rev Shark" DePorre

 | Oct 28, 2016 | 11:28 AM EDT
We may see a respite of the recent pressure for a few days, but it can't be trusted to last.
RMPIA
By

Bruce Kamich

 | Oct 17, 2016 | 3:34 PM EDT
AMGN is neutral now, but a close below $158 weakens the chart picture.
RMPIA
By

Bret Jensen

 | Oct 10, 2016 | 12:00 PM EDT
Both it and Ligand Pharmaceuticals look significantly undervalued relative to their prospects.
RMPIA
By

Timothy Collins

 | Sep 16, 2016 | 1:30 PM EDT
The once-mighty biotech has fallen, but entry opportunities will surface.
RMPIA
By

Robert Lang

 | Sep 14, 2016 | 10:00 AM EDT
The shares have some power and legs to get up and through old highs.
From The Restaurant Finance Monitor...


...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.